

CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

August 14, 2026

To

BSE Limited

Phiroze Jeejeebhoy Towers, 25th Floor, Dalal
Street, Mumbai – 400 001

The National Stock Exchange of India Ltd

Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

We wish to inform you that the United States Food and Drug Administration (“US FDA”) has inspected our Unit 3 manufacturing facility, located at Gaddapotharam village, Jinnaram, Sangareddy District, from 10th to 14th of August 2026.

At the conclusion of the inspection, the US FDA issued a Form 483 with one observation. The observation pertains to procedural improvements in water and environmental monitoring to include new organisms beyond those listed in the United States Pharmacopeia (USP). The Company will submit its response to the US FDA within the stipulated timelines.

This is for your information and records.

Thanking you

Yours Sincerely,

For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary